Review Article| Volume 29, ISSUE 3, P543-553, September 2009

Point-of-Care Testing in Coagulation


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gardiner C.
        • Mackie S.
        • Mackie I.
        Point-of-care testing in hemostasis.
        in: Kitchen S. Olson J. Preston F.E. Quality in laboratory hemostasis and thrombosis. Wiley-Blackwell, Hoboken (NJ)2009: 72-80
        • Paniccia R.
        • Antonucci E.
        • Gori A.M.
        • et al.
        Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment.
        Am J Clin Pathol. 2007; 128: 143-149
        • Hayward C.P.
        • Harrison P.
        • Cattaneo M.
        • et al.
        Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.
        J Thromb Haemost. 2006; 4: 312-319
        • Schlammadinger A.
        • Kerenyi A.
        • Muszbek L.
        • et al.
        Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.
        Thromb Haemost. 2000; 84: 88-92
        • Campo G.
        • Valgimigli M.
        • Frangione A.
        • et al.
        Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI.
        J Thromb Haemost. 2008; 6: 1824-1826
        • Michelson A.D.
        • Cattaneo M.
        • Eikelboom J.W.
        • et al.
        Aspirin resistance: position paper of the Working Group on Aspirin Resistance.
        J Thromb Haemost. 2005; 3: 1309-1311
        • Patrono C.
        • Baigent C.
        • Hirsh J.
        • et al.
        Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).
        Chest. 2008; 133: 199S-233S
        • Douketis J.D.
        • Berger P.B.
        • Dunn A.S.
        • et al.
        The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).
        Chest. 2008; 133: 299S-339S
        • Campbell C.L.
        • Smyth S.
        • Montalescot G.
        • et al.
        Aspirin dose for the prevention of cardiovascular disease: a systematic review.
        JAMA. 2007; 297: 2018-2024
        • Gum P.A.
        • Kottke-Marchant K.
        • Welsh P.A.
        • et al.
        A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
        J Am Coll Cardiol. 2003; 41: 961-965
        • Bliden K.P.
        • DiChiara J.
        • Tantry U.S.
        • et al.
        Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?.
        J Am Coll Cardiol. 2007; 49: 657-666
        • Buonamici P.
        • Marcucci R.
        • Migliorini A.
        • et al.
        Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
        J Am Coll Cardiol. 2007; 49: 2312-2317
        • Chen W.H.
        • Cheng X.
        • Lee P.Y.
        • et al.
        Aspirin resistance and adverse clinical events in patients with coronary artery disease.
        Am J Med. 2007; 120: 631-635
        • Buch A.N.
        • Singh S.
        • Roy P.
        • et al.
        Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
        Am J Cardiol. 2007; 99: 1518-1522
        • Price M.J.
        • Endemann S.
        • Gollapudi R.R.
        • et al.
        Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
        Eur Heart J. 2008; 29: 992-1000
        • Marcucci R.
        • Gori A.M.
        • Paniccia R.
        • et al.
        Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
        Circulation. 2009; 119: 237-242
        • Patti G.
        • Nusca A.
        • Mangiacapra F.
        • et al.
        Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity predicts Outcome) study.
        J Am Coll Cardiol. 2008; 52: 1128-1133
        • Gianetti J.
        • Parri M.S.
        • Sbrana S.
        • et al.
        Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study.
        Thromb Res. 2006; 118: 487-493
        • Marcucci R.
        • Paniccia R.
        • Antonucci E.
        • et al.
        Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
        Am J Cardiol. 2006; 98: 1156-1159
        • Andersen K.
        • Hurlen M.
        • Arnesen H.
        • et al.
        Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.
        Thromb Res. 2002; 108: 37-42
        • Pamukcu B.
        • Oflaz H.
        • Onur I.
        • et al.
        Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
        Blood Coagul Fibrinolysis. 2007; 18: 187-192
        • Mega J.L.
        • Close S.L.
        • Wiviott S.D.
        • et al.
        Cytochrome p-450 polymorphisms and response to clopidogrel.
        N Engl J Med. 2009; 360: 354-362
        • Simon T.
        • Verstuyft C.
        • Mary-Krause M.
        • et al.
        Genetic determinants of response to clopidogrel and cardiovascular events.
        N Engl J Med. 2009; 360: 363-375
        • Ho P.M.
        • Maddox T.M.
        • Wang L.
        • et al.
        Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
        JAMA. 2009; 301: 937-944
        • Juurlink D.N.
        • Gomes T.
        • Ko D.T.
        • et al.
        A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
        CMAJ. 2009; 180: 713-718
        • Freedman J.E.
        • Hylek E.M.
        Clopidogrel, genetics, and drug responsiveness.
        N Engl J Med. 2009; 360: 411-413
        • Poller L.
        • Keown M.
        • Ibrahim S.A.
        • et al.
        Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment.
        Clin Chem. 2006; 52: 1843-1847
        • Christensen T.D.
        • Larsen T.B.
        • Jensen C.
        • et al.
        International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy.
        Thromb Haemost. 2009; 101: 563-569
        • Karon B.S.
        • McBane R.D.
        • Chaudhry R.
        • et al.
        Accuracy of capillary whole blood international normalized ratio on the CoaguChek S, CoaguChek XS, and i-STAT 1 point-of-care analyzers.
        Am J Clin Pathol. 2008; 130: 88-92
        • Siebenhofer A.
        • Rakovac I.
        • Kleespies C.
        • et al.
        Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial.
        Thromb Haemost. 2008; 100: 1089-1098
        • Deom A.
        • Reber G.
        • Tsakiris D.A.
        • et al.
        Evaluation of the CoaguChek XS Plus system in a Swiss community setting.
        Thromb Haemost. 2009; 101: 988-990
        • Torreiro E.G.
        • Fernandez E.G.
        • Rodriguez R.M.
        • et al.
        Comparative study of accuracy and clinical agreement of the CoaguChek XS portable device versus standard laboratory practice in unexperienced patients.
        Thromb Haemost. 2009; 101: 969-974
        • Heneghan C.
        • Alonso-Coello P.
        • Garcia-Alamino J.M.
        • et al.
        Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.
        Lancet. 2006; 367: 404-411
        • Ansell J.
        • Hirsh J.
        • Hylek E.
        • et al.
        Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).
        Chest. 2008; 133: 160S-198S
        • Anderson D.R.
        • Harrison L.
        • Hirsh J.
        Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy.
        Arch Intern Med. 1993; 153: 1441-1447
        • van den Besselar A.M.
        A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin.
        Thromb Haemost. 2000; 84: 410-412
        • Perry S.L.
        • Samsa G.P.
        • Ortel T.L.
        Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.
        Thromb Haemost. 2005; 94: 1196-1202
        • van den Besselaar A.M.
        • Witteveen E.
        • van der Meer F.J.
        Influence of haematocrit on international normalised ratio (INR) differences between a whole blood point-of-care coagulation monitor and reference prothrombin time in plasma.
        Thromb Haemost. 2008; 100: 1181-1184
        • Heim S.W.
        • Schectman J.M.
        • Siadaty M.S.
        • et al.
        D-dimer testing for deep venous thrombosis: a metaanalysis.
        Clin Chem. 2004; 50: 1136-1147
        • Reber G.
        • de Moerloose P.
        • Coquoz C.
        • et al.
        Comparison of two rapid D-dimer assays for the exclusion of venous thromboembolism.
        Blood Coagul Fibrinolysis. 1998; 9: 387-388
        • Kline J.A.
        • Israel E.G.
        • Michelson E.A.
        • et al.
        Diagnostic accuracy of a bedside D-dimer assay and alveolar dead-space measurement for rapid exclusion of pulmonary embolism: a multicenter study.
        JAMA. 2001; 285: 761-768
        • Ghys T.
        • Achtergael W.
        • Verschraegen I.
        • et al.
        Diagnostic accuracy of the Triage D-dimer test for exclusion of venous thromboembolism in outpatients.
        Thromb Res. 2008; 121: 735-741
        • Lee-Lewandrowski E.
        • Van Cott E.M.
        Evaluation of the Biosite Triage® quantitative whole blood D-dimer assay and comparison with the bioMerieux VIDAS® D-dimer exclusion test: validation and utility for use in the central laboratory and at the point of care.
        Point of Care. 2005; 4: 133-137
        • La'ulu S.L.
        • Dominguez C.M.
        • Roberts W.L.
        Performance characteristics of the AxSYM D-dimer assay.
        Clin Chim Acta. 2008; 390: 148-151
      1. Lee-Lewandrowski E, Nichols J, VanCott EM, et al. Implementation of a rapid whole blood D-dimer test in the emergency department of an urban academic medical center: impact on ED length of stay and ancillary test utilization. Am J Clin Pathol, in press.

        • Freyburger G.
        • Reboul M.P.
        • Labrouche S.
        • et al.
        Diagnosis accuracy of a new challenger for thrombosis exclusion, the Stratus CS DDMR.
        Clin Chim Acta. 2005; 354: 181-189
        • Reber G.
        • Bounameaux H.
        • Perrier A.
        • et al.
        A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism.
        Blood Coagul Fibrinolysis. 2004; 15: 435-438
        • Shitrit D.
        • Heyd J.
        • Raveh D.
        • et al.
        Diagnostic value of the D-dimer test in deep vein thrombosis: improved results by a new assay method and by using discriminate levels.
        Thromb Res. 2001; 102: 125-131
        • Shitrit D.
        • Levi H.
        • Huerta M.
        • et al.
        Appropriate indications for venous duplex scanning based on D-dimer assay.
        Ann Vasc Surg. 2002; 16: 304-308
        • Gosselin R.C.
        • Owings J.T.
        • Kehoe J.
        • et al.
        Comparison of six D-dimer methods in patients suspected of deep vein thrombosis.
        Blood Coagul Fibrinolysis. 2003; 14: 545-550
        • Schutgens R.E.
        • Haas F.J.
        • Gerritsen W.B.
        • et al.
        The usefulness of five D-dimer assays in the exclusion of deep venous thrombosis.
        J Thromb Haemost. 2003; 1: 976-981
        • Gardiner C.
        • Pennaneac'h C.
        • Walford C.
        • et al.
        An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis.
        Br J Haematol. 2005; 128: 842-848
        • Bucek R.A.
        • Quehenberger P.
        • Feliks I.
        • et al.
        Results of a new rapid d-dimer assay (cardiac d-dimer) in the diagnosis of deep vein thrombosis.
        Thromb Res. 2001; 103: 17-23
        • Dempfle C.E.
        • Korte W.
        • Schwab M.
        • et al.
        Sensitivity and specificity of a quantitative point of care D-dimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis.
        Thromb Haemost. 2006; 96: 79-83
        • Legnani C.
        • Fariselli S.
        • Cini M.
        • et al.
        A new rapid bedside assay for quantitative testing of D-dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis.
        Thromb Res. 2003; 111: 149-153
        • Arpino P.A.
        • Cronin-Jenkins S.
        • Misiano D.
        • et al.
        Comparing the activated clotting times obtained from 2 point-of-care devices in patients receiving unfractionated heparin during percutaneous coronary intervention.
        Point of Care. 2008; 7: 30-33
        • Chia S.
        • Van Cott E.M.
        • Raffel O.C.
        • et al.
        Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
        Thromb Haemost. 2009; 101: 535-540
        • Kratz A.
        • Van Cott E.M.
        Activated clotting time: methods and clinical applications.
        Point of Care. 2005; 4: 90-94
        • Mangano D.T.
        • Tudor I.C.
        • Dietzel C.
        The risk associated with aprotinin in cardiac surgery.
        N Engl J Med. 2006; 354: 353-365
        • Mangano D.T.
        • Miao Y.
        • Vuylsteke A.
        • et al.
        Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
        JAMA. 2007; 297: 471-479